

Logon

*** It is now 2/22/2008 9:06:33 AM ***

Welcome to DialogLink - Version 5

Revolutionize the Way You Work!

New on Dialog

Order Patent and Trademark File Histories Through Dialog

Thomson File Histories are now available directly through Dialog. Combined with the comprehensive patent and trademark information on Dialog, file histories give you the most complete

view of a patent or trademark and its history in one place. When searching in the following patent and trademark databases, a link to an online order form is displayed in your search

results, saving you time in obtaining the file histories you need.

Thomson File Histories are available from the following Dialog databases:

CLAIMS/Current Patent Legal Status (File 123)

CLAIMS/U.S. Patents (File 340)

Chinese Patent Abstracts in English (File 344)

Derwent Patents Citation Index (File 342)

Derwent World Patents Index (for users in Japan) (File 352)

Derwent World Patents Index First View (File 331)

Derwent World Patents Index (File 351)

Derwent World Patents Index (File 350)

Ei EnCompassPat (File 353)

European Patents Fulltext (File 348)

French Patents (File 371)

German Patents Fulltext (File 324)

IMS Patent Focus (File 447, 947)

INPADOC/Family and Legal Status (File 345)

JAPIO - Patent Abstracts of Japan (File 347)

LitAlert (File 670)

U.S. Patents Fulltext (1971-1975) (File 652)

U.S. Patents Fulltext (1976-present) (File 654)

WIPO/PCT Patents Fulltext (File 349)

TRADEMARKSCAN - U.S. Federal (File 226)

DialogLink 5 Release Notes

New features available in the latest release of DialogLink 5 (August 2006)

Ability to resize images for easier incorporation into DialogLink Reports

New settings allow users to be prompted to save Dialog search sessions in the format of their choice (Microsoft Word, RTF, PDF, HTML, or TEXT)

Ability to set up Dialog Alerts by Chemical Structures and the addition of Index Chemicus as a structure searchable database

Support for connections to STN Germany and STN Japan services

Show Preferences for details

? Help Log On Msg

*** ANNOUNCEMENTS ***

dialog.txt

"Thomson File Histories" are now available directly through Dialog in selected patent and trademark files. Combined with the comprehensive patent and trademark information on Dialog, file histories give you the most complete view of a patent or trademark and its history in one place. When searching in one of the patent and trademark databases, a link to an online order form is displayed in your search results, saving you time in obtaining the file histories you need. See HELP FILEHIST for more information about how to use the link and a list of files that contain the link.

The 2008 EMTREE Thesaurus has been added to EMBASE (Files 72, 73, 772, and 972)

RESUMED UPDATING

***File 156, ToxFile

RELOADS COMPLETED

***Files 154 & 155, MEDLINE (annual reload)

***Files 72 & 73, EMBASE

>>>For the latest news about Dialog products, services, content<<<
>>>and events, please visit What's New from Dialog at <<<
>>><http://www.dialog.com/whatsnew/>. You can find news about <<<
>>>a specific database by entering HELP NEWS <file number>. <<<

? Help Off Line

* * *

Connecting to oluwatosin ogunbiyi - Dialog - 294085

Connected to Dialog via SMS003133702

? b medicine

>>>W: 138 is unauthorized

1 of the specified files is not available

[File 5] Biosis Previews(R) 1926-2008/Feb W3

(c) 2008 The Thomson Corporation. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2008/Feb W4

(c) 2008 The Thomson Corp. All rights reserved.

[File 35] Dissertation Abs Online 1861-2007/Oct

(c) 2007 ProQuest Info&Learning. All rights reserved.

[File 45] EMCare 2008/Feb W3

(c) 2008 Elsevier B.V. All rights reserved.

[File 65] Inside Conferences 1993-2008/Feb 20

(c) 2008 BLDSC all rts. reserv. All rights reserved.

[File 71] ELSEVIER BIOBASE 1994-2008/Feb W3

(c) 2008 Elsevier B.V. All rights reserved.

[File 73] EMBASE 1974-2008/Feb 21

(c) 2008 Elsevier B.V. All rights reserved.

*File 73: The 2008 EMTREE Thesaurus has been loaded. Please see HELP NEWS 72 for details.

[File 91] MANTIS(TM) 1880-2007/Apr

2001 (c) Action Potential. All rights reserved.

*File 91: This database has stopped updating temporarily. Please see HELP NEWS 91 for details.

[File 98] General Sci Abs 1984-2008/Jan

(c) 2008 The HW Wilson Co. All rights reserved.

[File 135] NewsRx Weekly Reports 1995-2008/Feb W3
 (c) 2008 NewsRx. All rights reserved.
 [File 144] Pascal 1973-2008/Feb W3
 (c) 2008 INIST/CNRS. All rights reserved.
 [File 149] TGG Health&Wellness DB(SM) 1976-2008/Feb W1
 (c) 2008 The Gale Group. All rights reserved.
 [File 155] MEDLINE(R) 1950-2008/Feb 19
 (c) format only 2008 Dialog. All rights reserved.
 *File 155: MEDLINE has reloaded. Please see HELP NEWS 155 for details.
 [File 156] ToxFile 1965-2008/Feb W2
 (c) format only 2008 Dialog. All rights reserved.
 *File 156: ToxFile has resumed updating with the 2008 MeSH. Please see HELP NEWS154 for information.
 [File 159] Cancerlit 1975-2002/Oct
 (c) format only 2002 Dialog. All rights reserved.
 [File 162] Global Health 1983-2008/Dec
 (c) 2008 CAB International. All rights reserved.
 [File 164] Allied & Complementary Medicine 1984-2008/Feb
 (c) 2008 BLICIS. All rights reserved.
 [File 172] EMBASE Alert 2008/Jan 31
 (c) 2008 Elsevier B.V. All rights reserved.
 [File 266] FEDRIP 2007/Nov
 Comp & dist by NTIS, Intl Copyright All Rights Res. All rights reserved.
 [File 369] New Scientist 1994-2007/Sep W4
 (c) 2007 Reed Business Information Ltd. All rights reserved.
 [File 370] Science 1996-1999/Jul W3
 (c) 1999 AAAS. All rights reserved.
 *File 370: This file is closed (no updates). Use File 47 for more current information.
 [File 399] CA SEARCH(R) 1967-2007/UD=14808
 (c) 2008 American Chemical Society. All rights reserved.
 *File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=.
 See HELP NEWSIPCR.
 [File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 2006 The Thomson Corp. All rights reserved.
 [File 444] New England Journal of Med. 1985-2008/Dec W5
 (c) 2008 Mass. Med. Soc. All rights reserved.
 [File 467] ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd. All rights reserved.

? s cpg and mage and (il (w) 18) or interleukin (w) 18)

>>>W: Unmatched parentheses

>>>E: There is no result

? s cpg and mage and cancer

78792 CPG

8258 MAGE

5681958 CANCER

S1 139 S CPG AND MAGE AND CANCER

? s il (w) 18 or interleukin (w) 18

Processing

1449857 IL

3454307 18

20419 IL(W)18

1273712 INTERLEUKIN
3454307 18
19758 INTERLEUKIN(W)18
S2 27025 S IL (W) 18 OR INTERLEUKIN (W) 18

? s s1 and s2
139 S1
27025 S2
S3 3 S S1 AND S2

? rd
S4 3 RD (UNIQUE ITEMS)

? t s4/k/all
>>>W: KWIC option is not available in file(s): 399

? t s4/3/all
4/3/1 (Item 1 from file: 399) Links
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

142445992 CA: 142(24)445992r PATENT
Vaccine compositions comprising antigen and interleukin 18 and saponin adjuvant for treating infection, cancer and autoimmune disease

Inventor (Author): Bruck, Claudine Elvire Marie; Gerard, Catherine Marie Ghislaine; Jonak, Zdenka Ludmila
Location: Belg.

Assignee: Glaxosmithkline Biologicals Sa; Smithkline Beecham Corporation

Patent: PCT International ; WO 200539634 A1 Date: 20050506

Application: WO 2004EP11620 (20041011) *GB 200323965 (20031013)

Pages: 63 pp.

CODEN: PDXXD2

Language: English

Patent Classifications:

Class: A61K-039/39A; A61P-031/02B; A61P-031/12B; A61P-037/04B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;

HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;

SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR;

GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/2 (Item 2 from file: 399) Links
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

142445990 CA: 142(24)445990p PATENT
Vaccine compositions comprising antigen and interleukin 18 and CpG adjuvants against infection, cancer and autoimmune disease

dialog.txt

Inventor (Author): Bruck, Claudine Elvire Marie; Gerard, Catherine Marie Ghislaine; Jonak, Zdenka Ludmila
Location: Belg.

Assignee: Glaxosmithkline Biologicals S. A.; Smithkline Beecham Corporation

Patent: PCT International ; WO 200539630 A2 Date: 20050506

Application: WO 2004EP11621 (20041011) *GB 200323968 (20031013)

Pages: 48 pp.

CODEN: PLXXD2

Language: English

Patent Classifications:

Class: A61K-039/00A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;

HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;

SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR;

GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

4/3/3 (Item 3 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

138384138 CA: 138(25)384138k PATENT

Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell

Inventor (Author): Nieland, John; Breidenstein, Claudia; Sartorius, Ute; Moebius, Ulrich; Bogedain, Christoph; Dinkel, Adelheid

Location: Germany.

Assignee: Medigene Aktiengesellschaft

Patent: PCT International ; WO 200339591 A2 Date: 20030515

Application: WO 2002EP12526 (20021108) *US PV332497 (20011109)

Pages: 50 pp.

CODEN: PLXXD2

Language: German

Patent Classifications:

Class: A61K-039/00A; A61K-039/39B; A61P-035/00B; C12N-005/10B; C12N-015/864B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR;

TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;

CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

? s s1

S5 139 S S1

? rd

S6 68 RD (UNIQUE ITEMS)

? t s6 abnd 7909

>>>E: Set 6 abnd 7909 does not exist

? s s6 and 7909

68 S6

544 7909

S7 1 S S6 AND 7909

? t s7/3/all

7/3/1 (Item 1 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

02641925 Supplier Number: 135578777 (USE FORMAT 7 OR 9 FOR FULL TEXT)

New treatments for melanoma.(Advanced Practice)

Demierre, Marie-France; Allten, Sandy; Brown, Rebecca

Dermatology Nursing , 17 , 4 , 287(9)

August ,

2005

Publication Format: Magazine/Journal

ISSN: 1060-3441

Language: English

Record Type: Fulltext; Abstract Target Audience: Professional

Word Count: 5290 Line Count: 00577

? t s6/3/1-20

6/3/1 (Item 1 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

0019850333 Biosis No.: 200700510074

Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters

Author: Wischniewski Frank; Friese Olaf; Pantel Klaus; Schwarzenbach Heidi (Reprint)

Author Address: Univ Med Ctr Hamburg Effendorf, Inst Tumor Biol, Martinstr 52, D-20246 Hamburg, Germany**Germany

Author E-mail Address: hschwarz@uke.uni-hamburg.de

Journal: Molecular Cancer Research 5 (7): p 749-759 JUL 2007 2007

Item Identifier: doi:10.1158/1541-7786.MCR-06-0364

ISSN: 1541-7786

Document Type: Article

Record Type: Abstract

Language: English

6/3/2 (Item 2 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

0019611137 Biosis No.: 200700270878

Promoter hypomethylation in MAGE-A1 and-A3 genes in colorectal cancer cell lines and cancer tissues.

Author: Kim Kyung-Hee (Reprint); Choi Jin-Sung; Kim Il-Jin; Ku Ja-Lok; Park Jae-Gahb

Author Address: Seoul Natl Univ, Coll Med, Canc Res Inst, Cell Biol Lab, Seoul, South Korea **South Korea

Journal: Proceedings of the American Association for Cancer Research Annual Meeting 46 (Suppl. S): p 654-655 APR 2005 2005

Conference/Meeting: 96th Annual Meeting of the American-Association-for-Cancer-Research Anaheim, CA, USA April 16 -20, 2005; 20050416

Sponsor: Amer Assoc Canc Res

ISSN: 0197-016X

Document Type: Meeting; Meeting Abstract

Record Type: Citation

Language: English

6/3/3 (Item 3 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

19208251 Biosis No.: 200600553646

Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines

Author: Imura Masayoshi; Yamashita Satoshi; Cai Li-yi; Furuta Jun-ichi; Wakabayashi Mika; Yasugi Toshiharu; Ushijima Toshikazu (Reprint)

Author Address: Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan**Japan

Author E-mail Address: tushijim@nce.go.jp

Journal: Cancer Letters 241 (2): p 213-220 SEP 28 2006 2006

ISSN: 0304-3835

Document Type: Article

Record Type: Abstract

Language: English

6/3/4 (Item 4 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

19044847 Biosis No.: 200600390242

5' CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC

Author: Qiu Geng; Fang Jiancheng; He Yunshao (Reprint)

Author Address: Sun Yat Sen Univ, Sun Yat Sen Coll Med Sci, Da An Gene Diag Ctr, 72 Zhong Shan Rd 2, Guangzhou, Guangdong, Peoples R China**Peoples R China

Author E-mail Address: qiugeng928@yahoo.com; yshe@gzsums.edu.cn

Journal: Clinical Biochemistry 39 (3): p 259-266 MAR 2006 2006

ISSN: 0009-9120

Document Type: Article

Record Type: Abstract

Language: English

6/3/5 (Item 5 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

18600304 Biosis No.: 200510294804

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis

genes

Author: Vatolin Sergei; Abdullaev Ziedulla; Pack Svetlana D; Flanagan Patrick T; Custer Mary; Loukinov Dmitri I; Pugacheva Elena; Hong Julie A; Morse Herbert; Schrupp David S;

Risinger John I; Barrett J Carl; Lobanenko Victor V (Reprint)

Author Address: NIAID, Mol Pathol Sect, Immunopathol Lab, NIH, Twinbrook 1, Room 1417, MSC-8152, 5640 Fishers Lane, Rockville, MD 20852 USA**USA

Author E-mail Address: viobanenko@niaid.nih.gov

Journal: Cancer Research 65 (17): p 7751-7762 SEP 1 2005 2005

ISSN: 0008-5472

Document Type: Article

Record Type: Abstract

Language: English

6/3/6 (Item 6 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

18582767 Biosis No.: 200510277267

Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC

Author: Olaussen K A; Soria J-C; Park Y W; Kim H J; Kim S H; Ro J Y; Andre F; Jang S J (Reprint)

Author Address: Univ Ulsan, Dept Pathol, Asan Med Ctr, Coll Med, 388-1 Poongnap Dong, Seoul 138736, South Korea**South Korea

Author E-mail Address: jangsejin@amc.seoul.kr

Journal: European Journal of Cancer 41 (14): p 2112-2119 SEP 2005 2005

ISSN: 0959-8049

Document Type: Article

Record Type: Abstract

Language: English

6/3/7 (Item 7 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options
Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

18214452 Biosis No.: 200500121517

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine

Author: Sigalotti Luca; Fratta Elisabetta; Coral Sandra; Tanzarella Silvia; Danielli Riccardo; Colizzi Francesca; Fonsatti Ester; Traversari Catia; Altomonte Maresa; Maio Michele (Reprint)

Author Address: Dept Oncol/Div Med Oncol and Immunotherapy, Univ Hosp Siena, Str Delle Scotte 14, I-53100, Siena, Italy**Italy

Author E-mail Address: mmaio@cro.it

Journal: Cancer Research 64 (24): p 9167-9171 December 15, 2004 2004

Medium: print

ISSN: 0008-5472 _(ISSN print)

Document Type: Article

Record Type: Abstract

Language: English

6/3/8 (Item 8 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

17864008 Biosis No.: 200400233717

Demethylation of MAGE promoters during gastric cancer progression.

Author: Honda T; Tamura G (Reprint); Waki T; Kawata S; Terashima M; Nishizuka S; Motoyama T

Author Address: Department of Pathology, Yamagata University School of Medicine, Yamagata, Japan**Japan

Author E-mail Address: gtamura@med.id.yamagata-u.ac.jp

Journal: British Journal of Cancer 90 (4): p 838-843 23 February, 2004 2004

Medium: print

ISSN: 0007-0920 _(ISSN print)

Document Type: Article

Record Type: Abstract

Language: English

6/3/9 (Item 9 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

17080638 Biosis No.: 200300039357

The MAGE-A1 gene expression is not determined solely by methylation status of the promoter region in hematological malignancies.

Author: Suyama Takahiro (Reprint); Ohashi Haruhiko; Nagai Hirokazu; Hatano Sonoko; Asano Haruhiko; Murate Takashi;

Saito Hidehiko; Kinoshita Tomohiro

Author Address: First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku,

Nagoya, 466-8550, Japan**Japan

Author E-mail Address: takahirosuyama@hkg.odn.ne.jp

Journal: Leukemia Research 26 (12): p 1113-1118 December 2002 2002

Medium: print

ISSN: 0145-2126 _(ISSN print)

Document Type: Article

Record Type: Abstract

Language: English

6/3/10 (Item 10 from file: 5) Links

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

16877966 Biosis No.: 200200471477

DNA methylation in cancer: Too much, but also too little

Author: Ehrlich Melanie (Reprint)

dialog.txt

Author Address: Human Genetics Program, Department of Biochemistry, Tulane Medical School, SL31, New Orleans, LA, 70122, USA**USA

Journal: *Oncogene* 21 (35 Review Issue 3): p 5400-5413 12 August, 2002 2002

Medium: print

ISSN: 0950-9232

Document Type: Article

Record Type: Abstract

Language: English

6/3/11 (Item 11 from file: 5) [Links](#)

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

16393621 Biosis No.: 200100565460

Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis

Author: Jang Se J; Soria Jean-Charles; Wang Luo; Hassan Khaled A; Morice Rodolfo C; Walsh Garrett L; Hong Waun Ki; Mao Li (Reprint)

Author Address: Molecular Biology Laboratory, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe

Boulevard, Houston, TX, 77030, USA**USA

Journal: *Cancer Research* 61 (21): p 7959-7963 November 1, 2001 2001

Medium: print

ISSN: 0008-5472

Document Type: Article

Record Type: Abstract

Language: English

6/3/12 (Item 12 from file: 5) [Links](#)

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

15740264 Biosis No.: 200000458577

Promoter methylation directly controls the expression of MAGE-2, -3 and -4 genes in cutaneous melanoma

Author: Sigalotti L (Reprint); Coral S (Reprint); Nardi G (Reprint); Spessotto A (Reprint); Cattarossi I (Reprint); Colizzi F (Reprint); Altomonte M (Reprint); Maio M (Reprint)

Author Address: Advanced Immunotherapy Unit, Centro di Riferimento Oncologico, I.N.R.C.C.S., 33081, Aviano, Italy**Italy

Journal: *Journal of Immunotherapy* 23 (5): p 607 September-October, 2000 2000

Medium: print

Conference/Meeting: 15th Annual Scientific Meeting of the Society for Biological Therapy Seattle, Washington, USA October 26-29, 2000; 20001026

Sponsor: Society for Biological Therapy

Document Type: Meeting; Meeting Abstract

Record Type: Citation

Language: English

6/3/13 (Item 13 from file: 5) [Links](#)

Fulltext available through: STIC Full Text Retrieval Options

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

13565721 Biosis No.: 199699199781

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation

Author: Desmet Charles; De Backer Oliver; Faraoni Isabella; Lurquin Christophe; Brasseur Francis; Boon Thierry
Author Address: Ludwig Inst. Cancer Res., Universite Catholique de Louvain, 74 Ave. Hippocrate B-1200 Brussel, Belgium*Belgium
Journal: Proceedings of the National Academy of Sciences of the United States of America 93 (14) : p 7149-7153 1996
1996
ISSN: 0027-8424
Document Type: Article
Record Type: Abstract
Language: English

6/3/14 (Item 1 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

15751435 Genuine Article#: 101HQ No. References: 53

Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b

Author: James SR; Link PA; Karpf AR (REPRINT)

Corporate Source: New York State Dept Hlth,Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr,Elm & Carlton St/Buffalo/NY/14263 (REPRINT); New York State Dept

Hlth,Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr,Buffalo/NY/14263

Journal: ONCOGENE , 2006 , V 25 , N52 (NOV) , P 6975-6985

ISSN: 0950-9232 Publication date: 20061100

Publisher: NATURE PUBLISHING GROUP , MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/15 (Item 2 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

15663623 Genuine Article#: 094CD No. References: 22

Promoter hypomethylation and reactivation of MAGE-A1 and MAGE -A3 genes in colorectal cancer cell lines and cancer tissues

Author: Kim KH; Choi JS; Kim IJ; Ku JL (REPRINT) ; Park JG

Corporate Source: Seoul Natl Univ,Coll Med, Canc Res Inst, Cell Biol Lab,Korean Cell Line Bank,28 Yongon Dong/Seoul 110744//South Korea/ (REPRINT); Seoul Natl Univ,Coll Med, Canc

Res Inst, Cell Biol Lab,Korean Cell Line Bank,Seoul 110744//South Korea/ (kujalok@snu.ac.kr)

Journal: WORLD JOURNAL OF GASTROENTEROLOGY , 2006 , V 12 , N35 (SEP 21) , P 5651-5657

ISSN: 1007-9327 Publication date: 20060921

Publisher: W J G PRESS , PO BOX 2345, BEIJING 100023, PEOPLES R CHINA

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/16 (Item 3 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

15598489 Genuine Article#: 087WH No. References: 18

Oligonucleotide DNA chips are useful adjuncts in epigenetic studies of glioblastomas

Author: Kim B; Kim H; Song BJ; Cha SH; Lee MO; Park SH (REPRINT)

Corporate Source: Seoul Natl Univ, Coll Med, Dept Pathol, Yongon Dong 28/Seoul 110799//South Korea/ (REPRINT); Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799//South Korea/;

Inje Univ, Coll Med, Seoul//South Korea/; Catholic Med Sch, Dept Gen Surg, Seoul//South Korea/; GenoTech Corp, Seoul//South Korea/ (shparknp@plaza.snu.ac.kr)

Journal: NEUROPATHOLOGY , 2006 , V 26 , N 5 (OCT) , P 409-416

ISSN: 0919-6544 Publication date: 20061000

Publisher: BLACKWELL PUBLISHING , 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/17 (Item 4 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

15502656 Genuine Article#: 076HB No. References: 100

Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer

Author: Tamura G (REPRINT)

Corporate Source: Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi/Yamagata 9909585//Japan/ (REPRINT); Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585//Japan/ (

gtamura@med.id.yamagata-u.ac.jp)

Journal: WORLD JOURNAL OF GASTROENTEROLOGY , 2006 , V 12 , N 2 (JAN 14) , P 192-198

ISSN: 1007-9327 Publication date: 20060114

Publisher: W J G PRESS , PO BOX 2345, BEIJING 100023, PEOPLES R CHINA

Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

6/3/18 (Item 5 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

15034465 Genuine Article#: 029WE No. References: 52

Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells

Author: Lioriot A; De Plaen E; Boon T; De Smet C (REPRINT)

Corporate Source: Univ Catholique Louvain, Ludwig Inst Canc Res, Brussels Branch, 74 Ave Hippocrate/B-1200 Brussels//Belgium/ (REPRINT); Univ Catholique Louvain, Ludwig Inst Canc

Res, Brussels Branch, B-1200 Brussels//Belgium/; Univ Catholique Louvain, Cellular Genet Unit, B-1200 Brussels//Belgium/ (charles.desmet@bru.licr.org)

Journal: JOURNAL OF BIOLOGICAL CHEMISTRY , 2006 , V 281 , N 15 (APR 14) , P 10118-10126

ISSN: 0021-9258 Publication date: 20060414

Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC , 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/19 (Item 6 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

14535718 Genuine Article#: 98INK No. References: 39

Relationship between the extent of chromosomal losses and the pattern of CpG methylation in gastric carcinomas

Author: Hong SJ; Kim YH; Choi YD; Min KO; Choi SW; Rhyu MG (REPRINT)

Corporate Source: Catholic Univ Korea, Coll Med, Dept Microbiol, 505 Banpo Dong/Seoul 137701//South Korea/ (REPRINT); Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul

137701//South Korea/; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701//South Korea/; Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137701//South Korea/ (

rhyumung@catholic.ac.kr)

Journal: JOURNAL OF KOREAN MEDICAL SCIENCE , 2005 , V 20 , N5 (OCT) , P 790-805

ISSN: 1011-8934 Publication date: 20051000

Publisher: KOREAN ACAD MEDICAL SCIENCES , 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/20 (Item 7 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

13151129 Genuine Article#: 853PJ No. References: 21

A novel protein-DNA interaction involved with the CpG dinucleotide at-30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene

Author: Zhang H; Yu J; Gu J; Gao BM; Zhao YJ; Wang P; Zhang HY; De Zhu J (REPRINT)

Corporate Source: Shanghai Jiao Tong Univ, Inst Canc, State Key Lab Oncogenes & Related Genes, LN 2200-25, Xieta Rd/Shanghai 200032//Peoples R China/ (REPRINT); Shanghai Jiao

Tong Univ, Inst Canc, State Key Lab Oncogenes & Related Genes, Shanghai 200032//Peoples R China/ (zhujingde@yahoo.com)

Journal: CELL RESEARCH , 2004 , V 14 , N4 (AUG) , P 283-294

ISSN: 1001-0602 Publication date: 20040800

Publisher: SCIENCE CHINA PRESS , 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

? t s6/3/21-40

6/3/21 (Item 8 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

12108644 Genuine Article#: 728DV No. References: 54

Epigenetic targets for immune intervention in human malignancies

Author: Maio M (REPRINT) ; Coral S; Fratta E; Altomonte M; Sigalotti L

Corporate Source: IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occle 12/I-33081 Aviano/Italy/ (REPRINT); IRCCS, Ctr Riferimento

Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit,I-33081 Aviano//Italy/
Journal: ONCOGENE , 2003 , V 22 , N42 (SEP 29) , P 6484-6488
ISSN: 0950-9232 Publication date: 20030929
Publisher: NATURE PUBLISHING GROUP , MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW,
ENGLAND
Language: English Document Type: REVIEW (ABSTRACT AVAILABLE)

6/3/22 (Item 9 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
10294510 Genuine Article#: 509KK No. References: 33
Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma

Author: Sigalotti L; Coral S; Nardi G; Spessotto A; Cortini E; Cattarossi I; Colizzi F; Altomonte M; Maio M (REPRINT)
Corporate Source: IRCCS,Ctr Riferimento Oncol, Canc Bioimmunotherapy Unit,Via Pedemontant Occ 12/I-33081
Aviano//Italy/ (REPRINT); IRCCS,Ctr Riferimento Oncol, Canc

Bioimmunotherapy Unit,I-33081 Aviano//Italy/
Journal: JOURNAL OF IMMUNOTHERAPY , 2002 , V 25 , N1 (JAN-FEB) , P 16-26
ISSN: 1053-8550 Publication date: 20020100
Publisher: LIPPINCOTT WILLIAMS & WILKINS , 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/23 (Item 10 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
10003968 Genuine Article#: 473LT No. References: 54
Expression of HLA class I antigens and restoration of antigen-specific ctl response in melanoma cells following 5-aza-2'-deoxycytidine treatment

Author: Serrano A; Tanzarella S; Lionello I; Mendez R; Traversari C; Ruiz-Cabello F; Garrido F (REPRINT)
Corporate Source: Univ Granada,Hosp Univ Virgen de las Nieves, Serv Anal Clin,Avda Fuerzas Armadas S-N/E-18014
Granada//Spain/ (REPRINT); Univ Granada,Hosp Univ Virgen de las

Nieves, Serv Anal Clin,E-18014 Granada//Spain/; Ist Sci HS Raffaele,Canc Immunotherapy & Gene Therapy
Program,Milan//Italy/; GenEra SpA,Milan//Italy/
Journal: INTERNATIONAL JOURNAL OF CANCER , 2001 , V 94 , N2 (OCT 15) , P 243-251
ISSN: 0020-7136 Publication date: 20011015
Publisher: WILEY-LISS , DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

6/3/24 (Item 11 from file: 34) Links

Fulltext available through: STIC Full Text Retrieval Options
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
05406209 Genuine Article#: VW269 No. References: 25
METHYLATED CPG POINTS IDENTIFIED WITHIN MAGE-1 PROMOTER ARE INVOLVED IN GENE REPRESSION

dialog.txt

Author: SERRANO A; GARCIA A; ABRIL E; GARRIDO F; RUIZCABELLO F

Corporate Source: UNIV GRANADA,HOSP UNIV VIRGEN NIEVES,SERV ANAL CLIN & IMMUNOL,AVDA
CONSTITUC S-N/E-18014 GRANADA/SPAIN; UNIV GRANADA,HOSP

UNIV VIRGEN NIEVES,SERV ANAL CLIN & IMMUNOL/E-18014 GRANADA/SPAIN/

Journal: INTERNATIONAL JOURNAL OF CANCER , 1996 , V 68 , N4 (NOV 15) , P 464-470

ISSN: 0020-7136

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

6/3/25 (Item 1 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

03256567 2006075412

5prime CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC

Qiu G.; Fang J.; He Y.

Address: Y. He, Da An Gene Diagnosis Center, Sun Yat-sen College of Medical Science, Sun Yat-sen University, 72, Zhong
Shan Road II, Guangzhou, China

Email: yshe@gzsums.edu.cn

Journal : Clinical Biochemistry , 39/3 (259-266) , 2006 , United States

CODEN: CLBIA

ISSN: 0009-9120

Publisher Item Identifier: S0009912006000166

Document Type: Article

Languages: English Summary Languages: English

No. of References: 42

6/3/26 (Item 2 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

03157635 2005294180

Hypertonicity induction of melanoma antigen, a tumor-associated antigen

Park J.-H.; Lee S.-W.

Address: J.-H. Park, Department of Biology, Changwon National University, Changwon 641-773 , South Korea

Email: parkjh@sarim.changwon.ac.kr

Journal : Molecules and Cells , 13/2 (288-295) , 2002 , Germany

CODEN: MOCEE

ISSN: 1016-8478

Document Type: Article

Languages: English Summary Languages: English

No. of References: 42

6/3/27 (Item 3 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

02862639 2005016749

Promoter methylation profiling of 30 genes in human malignant melanoma

dialog.txt

Furuta J.; Umebayashi Y.; Miyamoto K.; Kikuchi K.; Otsuka F.; Sugimura T.; Ushijima T.
Address: T. Ushijima, Carcinogenesis Division, Natl. Cancer Ctr. Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo
104-0045, Japan
Email: tushijim@ncc.go.jp
Journal : Cancer Science , 95/12 (962-968) , 2004 , United Kingdom
CODEN: CSACC
ISSN: 1347-9032
Document Type: Article
Languages: English Summary Languages: English
No. of References: 48

6/3/28 (Item 4 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

02845372 2004322100

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-Aza-2prime-deoxycytidine

Sigalotti L.; Fratta E.; Coral S.; Tanzarella S.; Danielli R.; Colizzi F.; Fonsatti E.; Traversari C.; Altomonte M.; Maio M.
Address: M. Maio, Div. of Med. Oncol. and Immunother., Department of Oncology, University Hospital of Siena, Strada
delle Scotte 14, 53100 Siena , Italy

Email: mmaio@cro.it

Journal : Cancer Research , 64/24 (9167-9171) , 2004 , United States

PUBLICATION DATE: December 15, 2004

CODEN: CNREA

ISSN: 0008-5472

Document Type: Article

Languages: English Summary Languages: English

No. of References: 27

6/3/29 (Item 5 from file: 71) Links

Fulltext available through: STIC Full Text Retrieval Options

ELSEVIER BIOBASE

(c) 2008 Elsevier B.V. All rights reserved.

01328767 1999239992

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

De Smet C.; Lurquin C.; Lethe B.; Martelange V.; Boon T.

Address: T. Boon, Ludwig Institute for Cancer Research, Universite Catholique de Louvain, UCL 7479, 74 avenue
Hippocrate, B-1200 Bruxelles , Belgium

Email: boon@licr.ucl.ac.be

Journal : Molecular and Cellular Biology , 19/11 (7327-7335) , 1999 , United States

CODEN: MCEBD

ISSN: 0270-7306

Document Type: Article

Languages: English Summary Languages: English

No. of References: 53

6/3/30 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0082054227 EMBASE No: 2007474867

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Brichard V.G.; Lejeune D.

Cancer Immunotherapeutics R and D, GlaxoSmithKline Biologicals, Belgium

Author email: vincent.brichard@gskbio.com

Corresp. Author: Brichard V.G.

Corresp. Author Affil: Cancer Immunotherapeutics R and D, GlaxoSmithKline Biologicals, Belgium

Corresp. Author email: vincent.brichard@gskbio.com

Vaccine (Vaccine) (United Kingdom) September 27, 2007 , 25/SUPPL. 2 (B61-B71)

CODEN: VACCD ISSN: 0264410X

Publisher Item Identifier: S0264410X07007049

Item Identifier (DOI): 10.1016/j.vaccine.2007.06.038

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 92

6/3/31 (Item 2 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0080042008 EMBASE No: 2004227155

Promoter-dependent mechanism leading to selective hypomethylation within the 5prime region of gene MAGE-A1 in tumor cells

De Smet C.; Lorient A.; Boon T. // De Smet C.

Ludwig Institute for Cancer Research, Cellular Genetics Unit, Universite Catholique de Louvain, B1200 Brussels, Belgium

// Ludwig Institute for Cancer Research, Brussels Branch, 74

Avenue Hippocrate, B1200 Brussels, Belgium

Author email: charles.desmet@bru.lir.org; charles.desmet@bru.lir.org

Corresp. Author: De Smet C.

Corresp. Author Affil: Ludwig Institute for Cancer Research, Brussels Branch, 74 Avenue Hippocrate, B1200 Brussels,

Belgium

Corresp. Author email: charles.desmet@bru.lir.org

Molecular and Cellular Biology (Mol. Cell. Biol.) (United States) June 1, 2004 , 24/11 (4781-4790)

CODEN: MCEBD ISSN: 02707306

Item Identifier (DOI): 10.1128/MCB.24.11.4781-4790.2004

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 45

6/3/32 (Item 3 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0079207175 EMBASE No: 2002370971

Peptide-based cancer vaccines

dialog.txt

Machiels J.-P.; Van Baren N.; Marchand M. // Machiels J.-P.; Van Baren N.; Marchand M. // Marchand M.
Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Université De Louvain, Brussels, Belgium // Ludwig Institute
for Cancer Research, Brussels Branch, Brussels, Belgium //

Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Université De Louvain, Avenue Hippocrate 54, B-1200 Brussels, Belgium

Corresp. Author: Machiels J.-P.

Corresp. Author Affil: Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Université de Louvain, Avenue Hippocrate 54, B-1200 Brussels, Belgium

Seminars in Oncology (Semin. Oncol.) (United States) October 2, 2002 , 29/5 (494-502)

CODEN: SOLGA ISSN: 00937754

Item Identifier (DOI): 10.1053/sonc.2002.35244

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 54

6/3/33 (Item 1 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000666637 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New cancer research reported from F. Wischnewski and co-authors

Cancer Weekly, October 30, 2007, p.167

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

392

6/3/34 (Item 2 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000602617 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research on cancer therapy reported by scientists at University
Medical Center

Cancer Weekly, August 28, 2007, p.230

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

6/3/35 (Item 3 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000374795 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research from Japan, the United States and Switzerland yields new ovarian cancer data

Clinical Oncology Week, December 4, 2006, p.413

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1137

6/3/36 (Item 4 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000352156 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from National Cancer Center Research Institute further understanding of ovarian cancer

Clinical Oncology Week, October 30, 2006, p.597

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
407

6/3/37 (Item 5 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000335747 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent studies from the United States and Germany add new data to melanoma research

Cancer Vaccine Week, September 18, 2006, p.41

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

1168

6/3/38 (Item 6 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000329199 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New findings from Germany and the United Kingdom in the area of cancer treatment detailed

Cancer Vaccine Week, August 28, 2006, p.24

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

950

6/3/39 (Item 7 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000316010 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research from the United Kingdom, Switzerland and Germany add new data to cancer treatment body of knowledge

Biotech Business Week, July 10, 2006, p.255

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

1210

6/3/40 (Item 8 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000308890 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies from University of Ulsan, Seoul highlight latest research

Pharma Business Week, June 14, 2006, p.690

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1063

? t s6/3/41-68
6/3/41 (Item 9 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000295186 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Research from Japan and the South Korea in diagnostics provides new insights

Angiogenesis Weekly, May 5, 2006, p.55

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1046

6/3/42 (Item 10 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000293812 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Studies advance knowledge in lung cancer research

Cancer Weekly, April 24, 2006, p.359

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

1058

6/3/43 (Item 11 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000287148 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Findings describe new data in diagnostics research

Angiogenesis Weekly, March 31, 2006, p.38

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

1046

6/3/44 (Item 12 from file: 135) Links

NewsRx Weekly Reports

(c) 2008 NewsRx. All rights reserved.

0000269355 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' data advance diagnostics research

Cancer Weekly, January 10, 2006, p.110

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English

RECORD TYPE: FULLTEXT

Word Count:

1154

6/3/45 (Item 13 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000263255 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Abnormal gene promoter methylation detected in paraffin-embedded sputum
from patients with NSCLC

Cancer Weekly, December 13, 2005, p.175

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
424

6/3/46 (Item 14 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000245897 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Data advance knowledge in melanoma vaccines research

Cancer Gene Therapy Week, September 26, 2005, p.56

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
1123

6/3/47 (Item 15 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

0000196000 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Cancer antigen heterogeneity in melanoma is methylation-regulated

Cancer Vaccine Week, February 28, 2005, p.11

DOCUMENT TYPE: Editor's Choice LANGUAGE: English
RECORD TYPE: FULLTEXT

Word Count:
481

6/3/48 (Item 1 from file: 149) Links
TGG Health&Wellness DB(SM)
(c) 2008 The Gale Group. All rights reserved.
02641925 Supplier Number: 135578777 (USE FORMAT 7 OR 9 FOR FULL TEXT)
New treatments for melanoma.(Advanced Practice)

Demierre, Marie-France; Allten, Sandy; Brown, Rebecca
Dermatology Nursing , 17 , 4 , 287(9)
August ,
2005
Publication Format: Magazine/Journal
ISSN: 1060-3441
Language: English
Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 5290 Line Count: 00577

6/3/49 (Item 1 from file: 155) Links
Fulltext available through: STIC Full Text Retrieval Options
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
25902138 PMID: 18281780
[Gastric cancer: histological type, histogenesis, and gene abnormalities.]

Tamura Gen
Dept. of Pathology and Laboratory Medicine, Yamagata Prefectural Central Hospital.
Gan to kagaku ryoho. Cancer & chemotherapy (Japan) Feb 2008 , 35 (2) p343-9 , ISSN: 0385-0684--Print Journal
Code: 7810034
Publishing Model Print
Document type: English Abstract; Journal Article
Languages: JAPANESE
Main Citation Owner: NLM
Record type: In Data Review

6/3/50 (Item 2 from file: 155) Links
Fulltext available through: STIC Full Text Retrieval Options
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
25524826 PMID: 17957795
Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.

dialog.txt

Kholmanskikh Olga; Loriot Axelle; Brasseur Francis; De Plaen Etienne; De Smet Charles
Brussels Branch, Ludwig Institute for Cancer Research, Brussels Branch, Université Catholique de Louvain, Brussels, Belgium.
International journal of cancer. Journal international du cancer (United States) Feb 15 2008 , 122 (4) p777-84 , ISSN: 1097-0215--Electronic Journal Code: 0042124
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

6/3/51 (Item 3 from file: 155) Links
Fulltext available through: STIC Full Text Retrieval Options
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
15951007 PMID: 15353125

A novel protein-DNA interaction involved with the CpG dinucleotide at -30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene.

Zhang Jie; Yu Jian; Gu Jun; Gao Bao Mei; Zhao Ying Jun; Wang Peng; Zhang Hong Yu; De Zhu Jing
The State-key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, LN 2200/25, Xietu Road, Shanghai 200032, China.
Cell research (China) Aug 2004 , 14 (4) p283-94 , ISSN: 1001-0602--Print Journal Code: 9425763
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

6/3/52 (Item 4 from file: 155) Links
Fulltext available through: STIC Full Text Retrieval Options
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
14490363 PMID: 11818167

Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination.

Sun Xiangli; Hodge Lisa M; Jones Harlan P; Tabor Leslie; Simecka Jerry W
Department of Molecular Biology and Immunology, Institute for Cancer Research, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA.
Vaccine (England) Jan 31 2002 , 20 (9-10) p1466-74 , ISSN: 0264-410X--Print Journal Code: 8406899
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

6/3/53 (Item 1 from file: 266) Links
FEDRIP
Comp & dist by NTIS, Intl Copyright All Rights Res. All rights reserved.
00604774
Identifying No.: 1R21CA122270-01A1 Agency Code: CRISP

Epigenetic Potentiation of Interferon using Decitabine

Principal Investigator: SAMLOWSKI, WOLFRAM E

Address: WSAMLOWSKI@NVCANCER.ORG NEVADA CANCER INSTITUTE ONE BREAKTHROUGH WAY LAS VEGAS, NV 89135

Performing Org.: NEVADA CANCER INSTITUTE , LAS VEGAS , NEVADA

Sponsoring Org.: NATIONAL CANCER INSTITUTE

Dates: 2009/07/07 To 2008/31/09 Fy : 2007

6/3/54 (Item 1 from file: 399) Links

Fulltext available through: STIC Full Text Retrieval Options

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

148165219 CA: 148(8)165219r JOURNAL

The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer

Author: Kondo, Tetsuo; Zhu, Xuegong; Asa, Sylvia L.; Ezzat, Shereen

Location: Departments of Pathology, The Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Can.,

Journal: Clin. Cancer Res.

Date: 2007

Volume: 13 Number: 16 Pages: 4713-4720

CODEN: CCREF4

ISSN: 1078-0432

Language: English

Publisher: American Association for Cancer Research

6/3/55 (Item 2 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

148098512 CA: 148(5)98512r PATENT

Primers and probes for the detection and quantitation of MAGE-A3 gene expression in cancer diagnosis and the selection of immunotherapy

Inventor (Author): Coche, Thierry; Gruselle, Olivier

Location: Belg.

Assignee: Glaxosmithkline Biologicals SA

Patent: PCT International ; WO 2007147876 A2 Date: 20071227

Application: WO 2007EP56219 (20070621) *GB 200612342 (20060621)

Pages: 103pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

IPC/8 + Level Value Position Status Version Action Source Office:

C12Q-0001/68 A I F B 20060101 H EP

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH;

GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM;

PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ

dialog.txt

Designated Regional: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN;

GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/56 (Item 3 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

148031921 CA: 148(2)31921e PATENT

Treatment of MAGE positive cancers by administering compositions comprising MAGE antigen-fusion proteins, adjuvants, and/or immunostimulatory cytokine or chemokine

Inventor (Author): Brichard, Vincent; Lehmann, Frederic Francois Eugene

Location: Belg.

Assignee: Glaxosmithkline Biologicals SA

Patent: PCT International ; WO 2007137986 A2 Date: 20071206

Application: WO 2007EP55037 (20070524) *GB 200610547 (20060526) *GB 20077307 (20070416)

Pages: 52pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

IPC/R8 + Level Value Position Status Version Action Source Office:

C07K-0014/47 A I F B 20060101 H EP

A61K-0039/00 A I L B 20060101 H EP

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM;

GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH;

PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG

Designated Regional: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN;

GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/57 (Item 4 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

147069038 CA: 147(4)69038q JOURNAL

Identification of candidate methylation-responsive genes in ovarian cancer

Author: Menendez, Laura; Walker, DeEtte; Matyunina, Lilya V.; Dickerson, Erin B.; Bowen, Nathan J.; Polavarapu, Nalini; Benigno, Benedict B.; McDonald, John F.

Location: Department of Genetics, University of Georgia, Athens, GA, 30605, USA

Journal: Mol. Cancer

Date: 2007

Volume: 6, Pages: No pp. given

CODEN: MCOACG

Uniform Resource Locator (URL): <http://www.molecular-cancer.com/content/pdf/1476-4598-6-10.pdf>

Media Type: online computer file

ISSN: 1476-4598
Language: English
Publisher: BioMed Central Ltd.

6/3/58 (Item 5 from file: 399) Links
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

142445992 CA: 142(24)445992r PATENT
Vaccine compositions comprising antigen and interleukin 18 and saponin adjuvant for treating infection, cancer and autoimmune disease
Inventor (Author): Bruck, Claudine Elvire Marie; Gerard, Catherine Marie Ghislaine; Jonak, Zdenka Ludmila
Location: Belg.
Assignee: Glaxosmithkline Biologicals Sa; Smithkline Beecham Corporation
Patent: PCT International ; WO 200539634 A1 Date: 20050506
Application: WO 2004EP11620 (20041011) *GB 200323965 (20031013)
Pages: 63 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
Class: A61K-039/39A; A61P-031/02B; A61P-031/12B; A61P-037/04B
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;
SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR;
GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/59 (Item 6 from file: 399) Links
CA SEARCH(R)
(c) 2008 American Chemical Society. All rights reserved.

142445990 CA: 142(24)445990p PATENT
Vaccine compositions comprising antigen and interleukin 18 and CpG adjuvants against infection, cancer and autoimmune disease
Inventor (Author): Bruck, Claudine Elvire Marie; Gerard, Catherine Marie Ghislaine; Jonak, Zdenka Ludmila
Location: Belg.
Assignee: Glaxosmithkline Biologicals S. A.; Smithkline Beecham Corporation
Patent: PCT International ; WO 200539630 A2 Date: 20050506
Application: WO 2004EP11621 (20041011) *GB 200323968 (20031013)
Pages: 48 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
Class: A61K-039/00A
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR;

HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK;

SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW

Designated Regional: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR;

GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/60 (Item 7 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

140075940 CA: 140(6)75940z PATENT

Unmethylated CpG oligonucleotide-packaged virus-like particles for enhancing immune response of vaccines

Inventor (Author): Bachman, Martin F.; Renner, Wolfgang A.

Location: Switz.

Assignee: Cytos Biotechnology Ag

Patent: PCT International ; WO 200400351 A1 Date: 20031231

Application: WO 2003EP6541 (20030620) *US PV389898 (20020620)

Pages: 252 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: A61K-039/39A; A61P-037/04B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN;

TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK;

TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/61 (Item 8 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

140040881 CA: 140(4)40881d PATENT

Fusion proteins comprising choline binding domain and tumor antigen for cancer therapy

Inventor (Author): Cabezon Siliva, Teresa Elisa Virginia; Ellis, Jonathan H.; Gerard, Catherine Marie Ghislaine; Hamblin, Paul A.; Palmantier, Remi M.; Vinals Y De Bassols, Carlota

Location: Belg.

Assignee: Glaxosmithkline Biologicals S.A.; Glaxo Group Limited

Patent: PCT International ; WO 2003104272 A1 Date: 20031218

Application: WO 2003EP6096 (20030606) *GB 200213365 (20020611) *GB 2003914 (20030115)

Pages: 162 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: C07K-014/315A; A61K-039/385B; C12N-005/10B; C12N-015/62B; C12N-015/63B; A61K-038/16B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR;

TT; TZ; UA; UG; US; VZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK;

TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/62 (Item 9 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

139021040 CA: 139(2)21040s PATENT

Methods for treating cancer

Inventor (Author): Vicari, Alain P.; Caux, Christophe

Location: USA

Assignee: Schering Corporation

Patent: PCT International ; WO 200345431 A2 Date: 20030605

Application: WO 2002US38098 (20021126) *US PV333434 (20011127)

Pages: 47 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: A61K-039/395A; A61K-047/48B; A61K-031/7088B; A61K-031/405B; A61K-039/00B; A61K-038/19B

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP;

KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UZ; VC; VN; YU; ZA; ZM;

AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;

CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/63 (Item 10 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

138400402 CA: 138(26)400402z PATENT

Tumor vaccines using genetically modified cells that are not derived from the respective tumoral disease and carry at least one cytokine, chemokine and/or a co-stimulating mol.

Inventor (Author): Nieland, John; Breidenstein, Claudia; Dinkel, Adelheid; Sartorius, Ute

Location: Germany.

Assignee: Medigene Aktiengesellschaft

dialog.txt

Patent: PCT International ; WO 200345428 A2 Date: 20030605
Application: WO 2002EP13531 (20021129) *US PV334491 (20011130)
Pages: 59 pp.
CODEN: PIXXD2
Language: German
Patent Classifications:

Class: A61K-039/00A; C12N-005/10B; A61P-035/00B
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR;

TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;

CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/64 (Item 11 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

138384138 CA: 138(25)384138k PATENT

Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell

Inventor (Author): Nieland, John; Breidenstein, Claudia; Sartorius, Ute; Moebius, Ulrich; Bogedain, Christoph; Dinkel, Adelheid

Location: Germany,

Assignee: Medigene Aktiengesellschaft

Patent: PCT International ; WO 200339591 A2 Date: 20030515
Application: WO 2002EP12526 (20021108) *US PV332497 (20011109)
Pages: 50 pp.

CODEN: PIXXD2

Language: German

Patent Classifications:

Class: A61K-039/00A; A61K-039/39B; A61P-035/00B; C12N-005/10B; C12N-015/864B
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR;

TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;

CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/65 (Item 12 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

138270293 CA: 138(18)270293b PATENT

dialog.txt

Vaccine compositions comprising anti-CD4 antibody or immunostimulatory nucleic acid and antigen-coupled virus-like particles for enhancement of immune responses

Inventor (Author): Bachmann, Martin F.; Storni, Tazio; Lechner, Franziska

Location: Switz.

Assignee: Cytos Biotechnology A.-G.

Patent: PCT International ; WO 200324480 A2 Date: 20030327

Application: WO 2002184252 (20020916) *US PV318967 (20010914)

Pages: 243 pp.

CODEN: PLXXD2

Language: English

Patent Classifications:

Class: A61K-039/00A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT;

TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;

CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/66 (Item 13 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

138253722 CA: 138(17)253722y PATENT

Chemokine receptor agonists and antagonists

Inventor (Author): Caux, Christophe; Vanbervliet, Beatrice; Paturel, Carine; Vicari, Alain; Trinchieri, Giorgio; Briere, Francine; Bendriss-Vernere, Nathalie

Location: USA

Assignee: Schering Corporation

Patent: PCT International ; WO 200324404 A2 Date: 20030327

Application: WO 2002US29759 (20020919) *US PV323604 (20010920)

Pages: 55 pp.

CODEN: PLXXD2

Language: English

Patent Classifications:

Class: A61K-000A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP;

KG; KR; KZ; LC; LK; LR; LT; LU; LV; MA; MD; MG; MK; MN; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UZ; VC; VN; YU; ZA; ZM;

AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;

CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/67 (Item 14 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

136339479 CA: 136(22)339479v PATENT

Vaccines comprise cancer antigen and saponin and immunostimulatory oligonucleotide

Inventor (Author): Garçon, Nathalie; Gerard, Catherine Marie Ghislaine; Stephenne, Jean

Location: Belg.

Assignee: Smithkline Beecham Biologicals SA

Patent: PCT International ; WO 200232450 A2 Date: 20020425

Application: WO 2001EP11984 (20011016) *GB 200025573 (20001018) *GB 200025574 (20001018) *US 690921 (20001018)

Pages: 49 pp.

CODEN: PLXXD2

Language: English

Patent Classifications:

Class: A61K-039/00A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;

IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA;

UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA;

GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/68 (Item 15 from file: 399) Links

CA SEARCH(R)

(c) 2008 American Chemical Society. All rights reserved.

132106969 CA: 132(9)106969g PATENT

Chemokines as adjuvants of immune response

Inventor (Author): Caux, Christophe; Vanbervliet, Beatrice; Lebecque, Serge; Vicari, Alain; Dieu, Marie-Caroline

Location: Fr.

Assignee: Schering-Plough

Patent: European Pat. Appl. ; EP 974357 A1 Date: 20000126

Application: EP 98401799 (19980716)

Pages: 16 pp.

CODEN: EPXXDW

Language: English

Patent Classifications:

Class: A61K-038/19A

Designated Countries: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE; MC; PT; IE; SI; LT; LV; FI; RO

? t s6/3/30,32

6/3/30 (Item 1 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0082054227 EMBASE No: 2007474867

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Brichard V.G.; Lejeune D.

Cancer Immunotherapeutics R and D, GlaxoSmithKline Biologicals, Belgium

Author email: vincent.brichard@gskbio.com

Corresp. Author: Brichard V.G.

Corresp. Author Affil: Cancer Immunotherapeutics R and D, GlaxoSmithKline Biologicals, Belgium

Corresp. Author email: vincent.brichard@gskbio.com

Vaccine (Vaccine) (United Kingdom) September 27, 2007 , 25/SUPPL. 2 (B61-B71)

CODEN: VACCD ISSN: 0264410X

Publisher Item Identifier: S0264410X07007049

Item Identifier (DOI): 10.1016/j.vaccine.2007.06.038

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 92

6/3/32 (Item 3 from file: 73) Links

Fulltext available through: STIC Full Text Retrieval Options

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0079207175 EMBASE No: 2002370971

Peptide-based cancer vaccines

Machiels J.-P.; Van Baren N.; Marchand M. // Machiels J.-P.; Van Baren N.; Marchand M. // Marchand M.

Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Universite De Louvain, Brussels, Belgium // Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium //

Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Universite De Louvain, Avenue Hippocrate 54, B-1200 Brussels, Belgium

Corresp. Author: Machiels J.-P.

Corresp. Author Affil: Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Universite de Louvain, Avenue Hippocrate 54, B-1200 Brussels, Belgium

Seminars in Oncology (Semin. Oncol.) (United States) October 2, 2002 , 29/5 (494-502)

CODEN: SOLGA ISSN: 00937754

Item Identifier (DOI): 10.1053/sonc.2002.35244

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 54

? t s6/k/30,32

>>>W: KWIC option is not available in file(s): 399

6/K/30 (Item 1 from file: 73) Links

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

...specific clinical setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3

immunotherapy in NSCLC and has the potential to be applied to all tumor types...

Drug Descriptors:

alpha interferon--pharmacology--pd; antibody--pharmacology--pd; BCG vaccine ; cancer vaccine--clinical trial--ct; cancer vaccine--drug therapy--dt; CpG oligodeoxynucleotide;

cyclophosphamide--drug therapy--dt; epidermal growth factor receptor 2--clinical trial--ct; gamma interferon...

Medical Descriptors:

* cancer immunotherapy

...therapy--dt; kidney carcinoma--drug therapy--dt; leukemia--drug therapy --dt; lung non small cell cancer--drug therapy--dt; lung non small cell cancer--surgery--su; melanoma--drug

therapy--dt; metastasis --drug therapy--dt; methodology; nephritis--side effect--si; oncogene ras; pain--side effect--si; pancreas cancer--drug therapy--dt; point mutation; priority journal;

review; T cell lymphoma--drug therapy--dt; T...

SECTION HEADINGS:

Cancer

Immunology, Serology and Transplantation

Clinical and Experimental Pharmacology

Drug Literature Index

Adverse Reactions Titles

6/K/32 (Item 3 from file: 73) Links

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

Peptide-based cancer vaccines

The characterization of tumor antigens recognized by T lymphocytes has provided the opportunity to immunize cancer patients with well-defined peptides. Differentiation and

tumor-specific antigens are expressed in a significant proportion of patients with cancer. Pilot studies have involved many patients with melanoma. No major toxicity has been reported

after...

Drug Descriptors:

* cancer vaccine--clinical trial--ct; *cancer vaccine--drug therapy--dt; *cancer vaccine--intradermal drug administration--dl; * cancer vaccine--intramuscular drug administration--im; *

cancer vaccine--pharmaceutics--pr; *cancer vaccine --pharmacology--pd; *cancer vaccine--subcutaneous drug administration--sc; *peptide--clinical trial--ct; *peptide--drug

combination--cb; *peptide--drug...

Medical Descriptors:

* cancer--drug therapy--dt; *cancer--etiology--et; * cancer--prevention--pc

antigen expression; antigen recognition; article; cancer immunotherapy; cancer regression; clinical trial; CpG island; drug efficacy; drug formulation; drug megadose; drug response; drug

safety; human; inflammation--side effect...

Drug Terms (Uncontrolled): CpG oligonucleotide--drug combination--cb; isa 51; montanide isa 51 --drug combination--cb; peptide MAGE 1--clinical trial--ct; peptide MAGE 1--drug

combination--cb; peptide MAGE 1--drug therapy --dt; peptide MAGE 1--intradermal drug administration--dl; peptide MAGE 1--pharmacology--pd; peptide MAGE 1--subcutaneous drug

dialog.txt

administration--sc; peptide MAGE 3--adverse drug reaction--ae; peptide MAGE 3--clinical trial--ct; peptide MAGE 3--drug combination--cb; peptide MAGE 3--drug therapy--dt; peptide

MAGE 3--intradermal drug administration--dl; peptide MAGE 3 --intramuscular drug administration--im; peptide MAGE 3 --pharmacology--pd; peptide MAGE 3--subcutaneous drug

administration--sc; peptide MART 1--clinical trial--ct; peptide MART 1--drug... ..dt; peptide Pmel 17--intradermal drug administration--dl; peptide Pmel 17--pharmacology--pd; recombinant

peptide MAGE 3--pharmacology--pd; sb as 2--drug combination--cb; tetanus 24 mer--drug combination--cb...

SECTION HEADINGS:

Cancer
Immunology, Serology and Transplantation
Drug Literature Index
Adverse Reactions Titles
Pharmacy

? s tumor and mage and adjuvant and cpg (w) 7909

5244870 TUMOR

8258 MAGE

444861 ADJUVANT

78792 CPG

544 7909

345 CPG(W)7909

S8 1 S TUMOR AND MAGE AND ADJUVANT AND CPG (W) 7909

? t s8/3/all

8/3/1 (Item 1 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

02641925 Supplier Number: 135578777 (USE FORMAT 7 OR 9 FOR FULL TEXT)

New treatments for melanoma.(Advanced Practice)

Demierre, Marie-France; Allten, Sandy; Brown, Rebecca

Dermatology Nursing , 17 , 4 , 287(9)

August ,

2005

Publication Format: Magazine/Journal

ISSN: 1060-3441

Language: English

Record Type: Fulltext; Abstract Target Audience: Professional

Word Count: 5290 Line Count: 00577

? e u=bruck, claudine

Ref Items Index-term

E1 0 U=BRUCK, CLAUDINE

E2 3 AA=AAD

E3 1 AA=AAD AAI144136

E4 1 AA=AAD AAI303025

E5 1 AA=AAD C

E6 1 AA=AAD T

E7 1 AA=AADAAIC399734
 E8 1 AA=AADAAIC399735
 E9 1 AA=AADAAIC399736
 E10 1 AA=AADAAIC399737
 E11 1 AA=AADAAIC399738
 E12 1 AA=AADAAIC399739
 E13 1 AA=AADAAIC399740
 E14 1 AA=AADAAIC399741
 E15 1 AA=AADAAIC399742
 E16 1 AA=AADAAIC399743
 E17 1 AA=AADAAIC399744
 E18 1 AA=AADAAIC399909
 E19 1 AA=AADAAIC399910
 E20 1 AA=AADAAIC399911
 E21 1 AA=AADAAIC399912
 E22 1 AA=AADAAIC399913
 E23 1 AA=AADAAIC399914
 E24 1 AA=AADAAIC399915
 E25 1 AA=AADAAIC399916

Enter PAGE for more

? e au=gerard, catherine

Ref Items Index-term

E1 2 AU=GERARD, CAROLINE
 E2 1 AU=GERARD, CASTRO RICHARD
 E3 33 AU=GERARD, CATHERINE
 E4 4 AU=GERARD, CATHERINE M.
 E5 11 AU=GERARD, CATHERINE MARIE GHISLAINE
 E6 1 AU=GERARD, CHAVANCY
 E7 1 AU=GERARD, CHERYL B.
 E8 5 AU=GERARD, CHRISTELLE
 E9 22 AU=GERARD, CHRISTIAN
 E10 6 AU=GERARD, CHRISTINE
 E11 1 AU=GERARD, CHRISTINE A.
 E12 6 AU=GERARD, CHRISTOPHER J.
 E13 1 AU=GERARD, CHRISTOPHER JOHN
 E14 7 AU=GERARD, CLAUDE
 E15 1 AU=GERARD, CLAUDE PIERRE
 E16 3 AU=GERARD, CLAUDIA
 E17 1 AU=GERARD, CLAUDIA M.
 E18 1 AU=GERARD, CLAUDINE
 E19 1 AU=GERARD, CLEVELAND J.
 E20 1 AU=GERARD, COLLERY THOMAS
 E21 17 AU=GERARD, CORINNE
 E22 1 AU=GERARD, COUDERT
 E23 185 AU=GERARD, CRAIG
 E24 1 AU=GERARD, CRAIG G.
 E25 13 AU=GERARD, CRAIG J.

Enter PAGE for more

? s e3

S9 33 AU='GERARD, CATHERINE'

? d s

Set Items Description

S1 139 S CPG AND MAGE AND CANCER
 S2 27025 S IL (W) 18 OR INTERLEUKIN (W) 18
 S3 3 S S1 AND S2
 S4 3 RD (unique items)
 S5 139 S S1
 S6 68 RD (unique items)
 S7 1 S S6 AND 7909
 S8 1 S TUMOR AND MAGE AND ADJUVANT AND CPG (W) 7909
 S9 33 AU='GERARD, CATHERINE' FROM 5, 34, 35, 45, 65, 71, 73, 91, 98, 135, 144, 149, 155, 156, 159, 162, 164, 172, 266, 369, 370, 399, 434, 444, 467

? s s1 and s9

139 S1

33 S9

S10 0 S S1 AND S9

? e au= jonak, zdenka

Ref Items Index-term

E1 6 AU=JONAK, Z. L.
 E2 4 AU=JONAK, ZDENKA
 E3 31 AU=JONAK, ZDENKA L.
 E4 1 AU=JONAK, ZDENKA L. P.
 E5 6 AU=JONAK, ZDENKA LUDMILA
 E6 1 AU=JONAK, ZOE
 E7 1 AU=JONAKAIT G
 E8 195 AU=JONAKAIT G M
 E9 33 AU=JONAKAIT G MILLER
 E10 64 AU=JONAKAIT G.M.
 E11 1 AU=JONAKAIT G.MILLER
 E12 67 AU=JONAKAIT GM
 E13 1 AU=JONAKAIT M.
 E14 1 AU=JONAKAIT RN
 E15 9 AU=JONAKAIT, G. M.
 E16 49 AU=JONAKAIT, G. MILLER
 E17 1 AU=JONAKAIT, G.M.
 E18 2 AU=JONAKAIT, GENE MILLER
 E19 1 AU=JONAKAIT, R. N.
 E20 1 AU=JONAKAIT, RANDOLPH N.
 E21 3 AU=JONAKAUER I
 E22 1 AU=JONAKI, J.
 E23 1 AU=JONAKIN CC
 E24 4 AU=JONAKIN J
 E25 2 AU=JONAKIN W L

Enter PAGE for more

? s e3

S11 31 AU='JONAK, ZDENKA L.'

? s s1 and s11

139 S1

31 S11

S12 0 S S1 AND S11

? s (cancer or tumor or tumour) and cpg and adjuvant

Processing

5681958 CANCER
5244870 TUMOR
747987 TUMOUR
78792 CPG
444861 ADJUVANT
S13 1177 S (CANCER OR TUMOR OR TUMOUR) AND CPG AND ADJUVANT

? s s11 and s13
31 S11
1177 S13
S14 0 S S11 AND S13

? s mage
S15 8258 S MAGE

? s s13 and s15
1177 S13
8258 S15
S16 23 S S13 AND S15

? rd
S17 23 RD (UNIQUE ITEMS)

? t s17/k/all
>>>W: KWIC option is not available in file(s): 399
17/K/1 (Item 1 from file: 73) Links

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply characterized. Several different approaches

aimed at targeting these antigens... In this field, the GSK Biologicals' approach relying on recombinant proteins combined with an immunological Adjuvant System in a specific clinical

setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3 immunotherapy in NSCLC and

has the potential to be applied to all tumor types. (c) 2007 Elsevier Ltd. All rights reserved.

Drug Descriptors:

alpha interferon--pharmacology--pd; antibody--pharmacology--pd; BCG vaccine ; cancer vaccine--clinical trial--ct; cancer vaccine--drug therapy--dt; CpG oligodeoxynucleotide;

cyclophosphamide--drug therapy--dt; epidermal growth factor receptor 2--clinical trial--ct; gamma interferon... ..therapy--dt; glycoprotein gp 100--drug therapy--dt; granulocyte

macrophage colony stimulating factor; imiquimod; immunological adjuvant--drug combination--cb; immunological adjuvant--drug therapy--dt; interferon--drug therapy--dt; interleukin

2--drug combination --cb; interleukin 2--drug...

Medical Descriptors:

* cancer immunotherapy

adjuvant therapy; B cell lymphoma--drug therapy--dt; chronic myeloid leukemia--drug therapy--dt; chronic obstructive... ..therapy--dt; kidney carcinoma--drug therapy--dt; leukemia--drug

therapy--dt; lung non small cell cancer--drug therapy--dt; lung non small cell cancer--surgery--su; melanoma--drug therapy--dt; metastasis --drug therapy--dt; methodology;

nephritis--side effect--si; oncogene ras; pain--side effect--si; pancreas cancer--drug therapy--dt; point mutation; priority journal; review; T cell lymphoma--drug therapy--dt; T lymphocyte;

tumor; uveitis--side effect--si

SECTION HEADINGS:

Cancer

Immunology, Serology and Transplantation

Clinical and Experimental Pharmacology

Drug Literature Index

Adverse Reactions Titles

17/K/2 (Item 2 from file: 73) Links

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

Peptide-based cancer vaccines

The characterization of tumor antigens recognized by T lymphocytes has provided the opportunity to immunize cancer patients with well-defined peptides. Differentiation and

tumor-specific antigens are expressed in a significant proportion of patients with cancer. Pilot studies have involved many patients with melanoma. No major toxicity has been reported

after... ..and long-lasting. The development of this approach, and that of other methods to deliver tumor antigens, depends on clinical empirism to improve the therapeutic efficacy of the

vaccine as well...

Drug Descriptors:

* cancer vaccine--clinical trial--ct; *cancer vaccine--drug therapy--dt; *cancer vaccine--intradermal drug administration--dl; * cancer vaccine--intramuscular drug administration--im; *

cancer vaccine--pharmaceutics--pr; *cancer vaccine --pharmacology--pd; *cancer vaccine--subcutaneous drug administration--sc; *peptide--clinical trial--ct; *peptide--drug

combination--cb; *peptide--drug...

differentiation antigen; Freund adjuvant--drug combination--cb; glycoprotein gp 100--clinical trial--ct; glycoprotein gp 100--drug therapy --dt... ..colony stimulating

factor--pharmacology--pd; granulocyte macrophage colony stimulating factor--subcutaneous drug administration--sc; immunological adjuvant--drug combination--cb; interleukin 12

--clinical trial--ct; interleukin 12--drug combination--cb; interleukin 12drug therapy--dt; recombinant antigen--intramuscular drug administration --im; recombinant

antigen--pharmacology--pd; sodium chloride; tumor antigen; unclassified drug

Medical Descriptors:

* cancer--drug therapy--dt; *cancer--etiology--et; * cancer--prevention--pc

antigen expression; antigen recognition; article; cancer immunotherapy; cancer regression; clinical trial; CpG island; drug efficacy; drug formulation; drug megadose; drug response; drug

safety; human; inflammation--side effect...

dialog.txt

Drug Terms (Uncontrolled): CpG oligonucleotide--drug combination--cb; isa 51; montanide isa 51 --drug combination--cb; peptide MAGE 1--clinical trial--ct; peptide MAGE 1--drug

combination--cb; peptide MAGE 1--drug therapy --dt; peptide MAGE 1--intradermal drug administration--dl; peptide MAGE 1--pharmacology--pd; peptide MAGE 1--subcutaneous drug

administration--sc; peptide MAGE 3--adverse drug reaction--ae; peptide MAGE 3--clinical trial--ct; peptide MAGE 3--drug combination--cb; peptide MAGE 3--drug therapy--dt; peptide

MAGE 3--intradermal drug administration--dl; peptide MAGE 3 --intramuscular drug administration--im; peptide MAGE 3 --pharmacology--pd; peptide MAGE 3--subcutaneous drug

administration --sc; peptide MART 1--clinical trial--ct; peptide MART 1--drug... ..dt; peptide Pmel 17--intradermal drug administration--dl; peptide Pmel 17--pharmacology--pd; recombinant

peptide MAGE 3--pharmacology--pd; sb as 2--drug combination--cb; tetanus 24 mer--drug combination--cb...
CAS Registry Number: 9007-81-2 (Freund adjuvant); 138415-13-1 (interleukin 12); 9002-10-2 (monophenol monooxygenase); 9054-49-3 (n acetylglucosaminyltransferase...

SECTION HEADINGS:

Cancer
Immunology, Serology and Transplantation
Drug Literature Index
Adverse Reactions Titles
Pharmacy

17/K/3 (Item 1 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

TEXT: Investigators in the United States and Germany have published new melanoma data.

Study 1: CpG-ODN enhances immunostimulatory effects of dendritic cell-based immunotherapy in a murine melanoma model.

"In this study, we examined the protective and therapeutic efficacy of the immuno-adjuvant CpG in combination with dendritic cell (DC) immunotherapy in a murine melanoma model," investigators in the United States report.

"We found that murine bone-marrow-derived DC stimulated in vitro with CpG displayed both enhanced expression of maturation markers and secretion of IL-12p70 and IL-10," said Shari Pilon-Thomas and colleagues at the H. Lee Moffitt Cancer Center. "In addition, these matured DC demonstrated enhanced ability to stimulate antigen specific CD4+ and...

...vitro. In a protection model, C57BL/6 mice vaccinated with either antigen-pulsed immature or CpG matured DC were unable to reject a lethal B16 melanoma challenge. In contrast, long-term protection was achieved in mice vaccinated with both CpG and antigen-pulsed DC, which correlated with an enhanced antigen-specific T cell immune response."

"In a therapeutic model of established subcutaneous B16 melanoma, C57BL/6 mice treated intratumorally with CpG and B16 lysate-pulsed DC demonstrated a reduced tumor burden and prolonged survival," the researchers reported. "In a similar model of established subcutaneous tumor, mice treated with CpG-matured DC pulsed with a

melanoma peptide, TRP-2, alone were unable to achieve tumor regression. Conversely, mice that received the combined vaccine of CpG and peptide-pulsed DC displayed a reduced tumor burden."

The scientists concluded, "These experiments provide evidence that combined immunization with both antigen-pulsed DC and the immunoadjuvant CpG can lead to tumor regression and long-term survival in a murine B16 melanoma model."

Pilon-Thomas and associates published their study in the *Journal of Immunotherapy* (Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. *J Immunother*, 2006;29

...

...contact Shari Pilon-Thomas, Division of Cutaneous Oncology, Immunology and Immunotherapy Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA. pilontsa@moffitt.usf.edu...

...attractive model disease for the development of antigen-specific immunotherapy because many antigens recognized by tumor-specific T cells have been identified.

"In C57BL/6 mice, genetic immunization with recombinant adenovirus... B16 melanoma cells," wrote D. Tormo and colleagues, University of Bonn.

"Here, we additionally applied CpG DNA and synthetic double-stranded RNA, which activate the innate immune system via TLR. Both

...

...the skin and reduction in the number of spontaneous lung metastases but did not induce tumor regression.

"Carcinogen-treated HGF X CDK4(R24C) mice bearing multiple autochthonous melanomas did not reject transplanted B16 melanoma despite treatment with Ad-hTRP2 and TLR ligands, suggesting the development of tumor immunotolerance," wrote the investigators.

They concluded, "Further investigations in our novel genetic melanoma model may...

...pathogenesis and treatment of this life-threatening disease."

Tormo and colleagues published their study in *Cancer Research* (Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. *Cancer Res*, 2006;66(10):5427-5435).

For more information, contact T. Tuting, University of Bonn...

...vaccine was loaded with peptides derived from four melanoma tissue differentiation antigens (MART-1, tyrosinase, MAGE-3, and gp100) and influenza matrix peptide (Flu-MP)," scientists writing in the *Journal of Immunology*, 2006;176(1):100-107. jacquesb@baylorhealth.edu.

Keywords: Dallas, Texas, United States, Melanoma Vaccine, Vaccine Development, Cancer Vaccine, Dendritic Cell Vaccine, Immunology, Immunotherapy, Skin Cancer, Oncology.

This article was prepared by Cancer Vaccine Week editors from staff and other reports. Copyright 2006, Cancer Vaccine Week via NewsRx.com & NewsRx.net.

DESCRIPTORS: Cancer Vaccine; Cancer Vaccine; Dallas; Dendritic Cell Vaccine; Drug Development; Immunization;

dialog.txt

Immunology; Immunotherapy; Melanoma Vaccine; Oncology;
Pharmaceuticals; Skin Cancer; Texas; Therap;
United States; Vaccination; Vaccine Development; All
News; Professional News

17/K/4 (Item 2 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

New findings from Germany and the United Kingdom in the area of
cancer treatment detailed

TEXT: Data on cancer treatment are outlined in reports from
Germany and the United Kingdom.

Study 1: Vaccination with peptide cocktail-loaded dendritic cells was
safe and showed some promise in hormone-refractory prostate cancer
patients.

... report, "Immunotherapies might represent promising alternatives for
the treatment of patients with hormone-refractory prostate cancer
(HRPC). In a Phase I clinical trial, we evaluated a vaccination with
dendritic cells (DCs) loaded with a cocktail consisting of
HLA-A*0201-restricted peptides derived from five different prostate
cancer-associated antigens [prostate-specific antigen (PSA),
prostate-specific membrane antigen (PSMA), survivin, prostatein, transient
receptor...

...PCa."

Fuessel and her coauthors published their study in Prostate
(Vaccination of hormone-refractory prostate cancer patients with
peptide cocktail-loaded dendritic cells: Results of a Phase I clinical
trial. Prostate...

...of Medicine, Fetscherstrasse 74, D-01307 Dresden, Germany.
manfred.wirth@uniklinikum-dresden.de.

Study 2: CpG oligodeoxynucleotides (ODN) activate dendritic
cells in vivo and induce a functional and protective vaccine immunity...

...restricted epitope.

According to recent research from France, "The use of synthetic
peptides derived from tumor-associated antigens is attractive for
the development of antitumoral vaccines as far as strong adjuvants...

...human and mouse shared TERT HLA-A*0201 restricted modified cryptic
peptide by using ODN-CpG as adjuvant."

"Humanized transgenic mice were immunized with the TERT modified
cryptic peptide in the presence of ODN-CpG and compared to mice
immunized in IFA," explained said Sebastian Cornet and collaborators at
Vaxon Biotechnology and Institute Pasteur. "By contrast with IFA, we first
showed that, in vivo, ODN-CpG leads to the recruitment of dendritic
cells in the lymph nodes draining the injection site...

...of CD40 at their cell surface. Immunization against TERT peptide in the
presence of ODN-CpG rather than IFA led to a strong CD8 response and

can delayed mortality in an induced tumor model."

The researchers concluded, "Study of the CD8 response obtained after antigenic challenge suggested that a functional memory response is induced upon vaccination with ODN-CpG. Thus, MHC class I-restricted epitope in combination of ODN-CpG is a promising and rather simple cancer vaccine formulation."

Cornet and coauthors published their study in Vaccine (CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against...

...OX5 1GB, England.

Study 3: Scientists have optimized the organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides to enhance immunogenicity.

According to researchers in France, "Polyspecific tumor vaccination should offer broad control of tumor cells and reduce the risk of emergence of immune escape variants. We evaluated the capacity of a polypeptide composed of optimized cryptic peptides derived from three different universal tumor antigens (TERT, HER-2/neu and MAGE-A) to induce a polyspecific CD8 cell response both in vivo in HHID mice and in vitro in humans."

"A mixture of TERT988Y, HER-2/neu and MAGE-A peptides failed to induce a trispecific response," reported Sebastien Cornet and collaborators at Vaxon...

...Cornet and associates published their study in Vaccine (Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity. Vaccine, 2006;24(12):2102-2109).

For additional information, contact Kostas...

...Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

This article was prepared by Cancer Vaccine Week editors from staff and other reports. Copyright 2006, Cancer Vaccine Week via NewsRx.com & NewsRx.net.

DESCRIPTORS: Cancer Treatment; Cancer Vaccine; Drug Development; Immunization; Oncology; Peptide; Pharmaceuticals; Proteins; Proteomics; Technical University of Dresden, Germany; Therapy...

SUBJECT HEADING: Cancer Treatment

17/K/5 (Item 3 from file: 135) Links
NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.

Research from the United Kingdom, Switzerland and Germany add new data to cancer treatment body of knowledge

TEXT: New findings from the United Kingdom, Switzerland and Germany describe advances in cancer treatment.

Study 1: CpG oligodeoxynucleotides (ODN) activate dendritic

dialog.txt

cells in vivo and induce a functional and protective vaccine immunity...

According to recent research from France, "The use of synthetic peptides derived from tumor-associated antigens is attractive for the development of antitumoral vaccines as far as strong adjuvants...

...the human and mouse shared TERT.HLA-A*0201 restricted modified cryptic peptide by using ODN-CpG as adjuvant."

"Humanized transgenic mice were immunized with the TERT modified cryptic peptide in the presence of ODN-CpG and compared to mice immunized in IFA," explained said Sebastien Cornet and collaborators at Vaxon Biotechnology and Institute Pasteur. "By contrast with IFA, we first showed that, in vivo, ODN-CpG leads to the recruitment of dendritic cells in the lymph nodes draining the injection site...

...of CD40 at their cell surface. Immunization against TERT peptide in the presence of ODN-CpG rather than IFA led to a strong CD8 response and can delayed mortality in an induced tumor model."

The researchers concluded, "Study of the CD8 response obtained after antigenic challenge suggested that a functional memory response is induced upon vaccination with ODN-CpG. Thus, MHC class I-restricted epitope in combination of ODN-CpG is a promising and rather simple cancer vaccine formulation."

Cornet and coauthors published their study in Vaccine (CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against...
...Elsevier Science Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

Study 2: Anti-MAGE-3 immune targeting with the MAGE-3(113) peptide is a promising approach for gastrointestinal cancer treatment.

"In order to broaden the possibility for anti-MAGE-3 immune targeting, it is important to identify HLA-A24-restricted epitopes derived from MAGE-3, since HLA-A24 is one of the most common alleles in Japanese and Asian people. In the present study, we defined a new MAGE-3 derived, HLA-A24-binding peptide presented as a CTL epitope on gastrointestinal cancer cells. A panel of MAGE-3-derived peptides (9mer and 10mer) with the HLA-A24-binding motif was selected, and identification of MAGE-3-derived, HLA-A24-restricted CTL epitopes was performed by a reverse immunology approach," scientists in Japan reported.

"To induce MAGE-3-peptide specific CTLs, PBMCs were repeatedly stimulated with monocyte-derived, mature DCs pulsed with...

...then obtained from the CTL line by limiting dilution. The peptide-inducing CTLs revealed that MAGE-3(113)-peptide was reacted as a CTL epitope in a HLA-A24-restricted fashion...

...assays," wrote N. Miyagawa and colleagues, University of Yamanashi.

The researchers concluded: "In addition, the MAGE-3(113)-specific CTL clones, confirmed by tetramer assay, showed that the MAGE-3(113) epitope is naturally processed and presented as the CTL epitope on MAGE-3-expressing gastrointestinal cancer cells by evaluating the cold target inhibition assays. The newly identified MAGE-3(113)-peptide epitope is naturally processed and presented as the CTL epitope on MAGE-3-expressing gastrointestinal cancer

dialog.txt

cells, indicating that anti-MAGE-3 immune targeting with the MAGE-3(113) peptide is a promising approach for treatment."

Miyagawa and colleagues published their study in *Oncology* (A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. *Oncology*, 2006;70(1):54-62).

For additional information, contact K. Kono, University of...

...presented by HLA-DQ B1 03011.

"NY-ESO-1 is one of the most immunogenic cancer antigens eliciting strong humoral and cellular immune responses in patients with NY-ESO-1-expressing...

...by MHC class II molecules. CD4+ T cells of patients with NY-ESO-1-expressing cancer were presensitized with 18-mer overlapping synthetic peptides spanning the entire sequence of NY-ESO-1," scientists writing in the *International Journal of Cancer* report.

"Two partly overlapping NY-ESO-1 epitopes p49-66 and p55-72 were identified...

...used to monitor NY-ESO-1-specific spontaneous and vaccine-induced T-cell responses in cancer patients."

Karbach and her coauthors published their study in the *International Journal of Cancer* (Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. *Int J Cancer*, 2006;118(3):668-674).

Additional information can be obtained by contacting Elke Jaeger, Medizinische...

...Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt, Germany.

elke.jaeger@licr.org.

Keywords: Frankfurt, Germany, Cancer Vaccine, Vaccine Development, Vaccine Efficacy, Gene Therapy, Immunology, Immunotherapy, Oncology, Antigen Presentation, Proteomics.

This article...

DESCRIPTORS: Antigen Presentation; Cancer Gene Therapy; Cancer Treatment; Cancer Vaccine; Frankfurt; Gene Therapy; Germany; Immunology; Immunotherapy; Oncology; Proteomics; Treatment; Vaccine Development; Vaccine Efficacy; All...

SUBJECT HEADING: Cancer Treatment

17/K/6 (Item 1 from file: 149) Links

TGG Health&Wellness DB(SM)

(c) 2008 The Gale Group. All rights reserved.

Text:

...to increase (Geller et al., 2002), but melanoma remains a malignancy predominantly refractory to anti-cancer therapies. New strategies

are urgently needed, particularly as it has been predicted that growth and aging of the U.S. population could potentially double the cancer burden in the next 50 years (Edwards et al., 2002).

The occasional dramatic response of patients with metastatic melanoma to vaccination with allogeneic or autologous tumor preparations or antigenic proteins or protein fragments (peptides), has spurred extensive efforts to develop melanoma vaccines. Multicenter phase III adjuvant vaccine therapy studies are evaluating multiple different vaccines in several different clinical settings (see Table...

...several malignancies, is discussed in the context of melanoma.

Melanoma Vaccines

The need for effective adjuvant therapies and evidence that the immune system plays a prominent role in the development and...

...clinical efficacy, but minimal morbidity. Furthermore, the 2004 guidelines for melanoma from the National Comprehensive Cancer Network (NCCN) recommend that patients with melanomas (greater than or equal to) 4 mm be...

...an immediate immune response is triggered that signals immune cells to attack and contain pathogens/tumor cell antigens until a long-term and more specific response can be generated. Adaptive immunity...

...and promote resistance to local immunosuppressive factors secreted in melanoma. Indeed melanoma is a "smart" tumor, often able to "avoid," or suppress the immune system (Denierre, Swetter, & Sondak, in press).

Nonspecific...

...agents, generally vaccines, are designed to elicit a host immune response to known or unknown tumor associated antigens (examples of well known melanoma-associated antigens include tyrosinase, Mart-1/Melan-A, gp75, gp 100, MAGE).

Allogeneic cellular vaccines. Using the principle that melanoma-associated antigens are shared among a large...

...development of an allogeneic vaccine, generally prepared from cultured cell lines, should stimulate an anti-tumor immune response. There has been documented evidence that this type of vaccination could induce immune...

...prospective, randomized trials. Two allogeneic vaccines were evaluated in large-scale, randomized trials as an adjuvant therapy for melanoma. Both incorporated an immunologic adjuvant to incite sufficient local immune response to promote sensitization to tumor-associated antigens.

* Canvaxin(R). Canvaxin is an allogeneic vaccine comprising three viable irradiated melanoma cell...

...are used). The cell lines were chosen for their high content of immunogenic melanoma and tumor-associated antigens, and contain at least 11 known tumor-associated antigens such as MAGE-1,

MAGE-3, tyrosinase, gp100, gp75, and Mart1/Melan-A (Morton & Barth, 1996). This vaccine enhances the...

...consists of a lysate of two homogenized melanoma cell lines that are combined with the adjuvant DETOX ("detoxified Freund's adjuvant," comprising monophosphoryl lipid A and a purified mycobacterial cell-wall skeleton) (Mitchell, 1998; Mitchell, Harel...

...The Southwest Oncology Group completed a large (689 patients) randomized trial evaluating Melacine in the adjuvant setting (SWOG 9035). Patients with intermediate thickness (1.5-4.0 mm), node-negative melanoma ...

...in combination with interferon. This study closed in 2003 and results are eagerly awaited.

Autologous tumor vaccines: Melanoma vaccines tailored to individual patients. Another approach has consisted of using the patient's own tumor to create a vaccine, postulating that whatever relevant antigens do exist would be represented on that individual's tumor cells. Approaches have included both autologous cellular vaccines and dendritic cell vaccines. Autologous tumor vaccines require the surgical resection of a sample of the patient's melanoma, which can...

...the GM2 to the xenogeneic protein keyhole limpet hemocyanin (KLH) and included the saponin-derived adjuvant QS-21 (Chapman et al., 2000), resulting in a vaccine called GMK. A recent intergroup...

...humoral (B-cell) response, peptide vaccines are intended to stimulate T-cell based responses to tumor-specific antigens expressed on the surface of cells through a major histocompatibility complex (MHC) class...

...weakly immunogenic, and so they are typically delivered to the patient along with an immune adjuvant. These adjuvants, such as BCG or "incomplete Freund's adjuvant," are meant to induce inflammation and initiate the immune process (Weber, 2000). Cytokines, such as...

...regulation of antigen expression to escape immune destruction). Since not all individuals have the same tumor antigen expression profile, having multiple antigens and adding cytokines could further stimulate the immune system...

...preliminary data have indicated feasibility, minimal toxicity, clinical responses in 18% of patients along with tumor-specific T-cell responses in 50% to 60% of subjects (Belli et al., 2002), a...

...was initiated. This study compares a heat shock peptide vaccine (HSPPC-96) derived from autologous tumor to standard therapies (IL-2 and/or dacarbazine/temozolomide based therapy and/or complete tumor resection) in stage IV melanoma patients (see Table 2). This study closed in September 2004 as it had reached accrual.

CpG DNA vaccines. An exciting strategy has been to develop agonists of TLR9, a toll-like...

...and B cells. TLR9 recognizes a specific pattern of nucleotides in the DNA, known as CpG DNA, that is common in bacteria and viruses, but

uncommon in human DNA. Using synthetic CpG DNA sequences that mimic (copies) those found in pathogens, synthetic CpG sequences are capable of binding to and activating TLRg, thus becoming DNA agonists (Klinman, 2004...

...and an adaptive immune response, generating cytotoxic T cells (CTLs) and disease-specific (pathogen or tumor) antibodies. In addition, via activation of dendritic cells, TLR9 agonists fight against the development of immune tolerance to pathogens and cancers. CPG 7909 is a single-strand oligodeoxynucleotide (a TLR9 agonist), that has been optimized for potent modulation of innate immunity and subsequent adaptive immune functions. CPG 7909 injection is being studied as a targeted cancer immunotherapeutic and as an adjuvant to melanoma chemotherapy. A phase II study has been completed in patients with advanced melanoma...

...the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). This CTLA4 limits the therapeutic potency of cancer vaccines by decreasing T-cell function (Chambers, Kuhns, Egen, & Allison, 2001), which is critical in melanoma immunity. Blocking CTLA4 with a monoclonal antibody against CTLA4 showed increased tumor immunity in previously vaccinated stage IV melanoma (Hodi et al., 2003). To date, side effects...

...agents to reverse, suppress, or prevent molecular or histologic premalignant lesions from progressing to invasive cancer. The original definition also included treating patients who had undergone successful primary cancer treatment but were at increased risk of a second primary cancer. More recently, cancer delay has been emphasized as yet another goal of chemoprevention (Lippman & Hong, 2002). In breast...

...markers of early events of carcinogenesis; (c) follow leads from epidemiologic data, basic science, and cancer research literature with regards to the selection of candidate prevention agents; (d) screen low toxicity...

...validate surrogate endpoint biomarkers in melanoma that have both prognostic value (ability to predict subsequent cancer) and predictive value (ability to predict effectiveness of chemopreventive agents) (Armstrong, Taylor, & Meyskens, 2003).

To...

...of ongoing phase III trials (see Table 5) is in accordance with the National Comprehensive Cancer Network 2004 Melanoma guidelines of care. The results of ongoing phase III vaccine trials will...

...end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiology Biomarkers and Prevention, 12(7), 589-592.

Balch, C.M., Buzaid, A.C., Soong...

...N., Coit, D.G., et al. (2001). Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. Journal of Clinical Oncology, 19(16), 3635-3648.

Belli, F...

...Andreola, G., Sertoli, M.R., et al. (2002). Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. *Journal of Clinical Oncology*...

...et al. (2001). Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. *Cancer Research*, 61, 222-227.

Chambers, C.A., Kuhns, M.S., Egen, J.G., & Allison, J...

...2001). CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. *Annual Review of Immunology*, 19, 565-594.

Chapman, P.B., Morrissey, D.M., Panageas...

...immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. *Clinical Cancer Research*, 6, 874-879.

Curjel-Lewandowski, C., & Demierre, M.F. (2000). Advances in specific immunotherapy...

...Demierre, M.F., Swetter, S., & Sondak, V. (2005). Vaccine therapy of melanoma: An update. *Current Cancer Therapy Reviews*, 1, 115-125.

DiFronzo, L.A., Gupta, R.K., Essner, R., Foshag, L...

...immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. *Journal of Clinical Oncology*, 20, 3242-3248.

Edwards, B.K., Howe, H.L...

...M., Yancik, R., et al. (2002). Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S.

cancer burden. *Cancer*, 94, 2766-2792.

Eisenbach, L., Bar-Haim, E., & El-Shami, K. (2000). Antitumor vaccination using...

...Bilchik, A.J., Yee, R., Leopoldo, Z., Ye, W., et al. (2001). CancerVax. An allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. *Annals of Surgical Oncology*, 8, 389-401.

Hersey, P., Sillar, R.W., Howe, C.G...

...trends in cutaneous melanoma incidence among whites in the United States. *Journal of the National Cancer Institute*, 93, 678-683.

Kirkwood, J.M., Ibrahim, J., Lawson, D.H., Atkins, M.B...

...C509801. *Journal of Clinical Oncology*, 19, 2370-2380.

Kliman, D.M. (2004). Immunotherapeutic uses of CpG oligodeoxynucleotides. *Nature Reviews Immunology*, 4, 249-258.

Lee, P., Wang, P., Kuniyoshi, J., Rubio, V...

...melanoma. *Journal of Clinical Oncology*, 19, 3836-3847.

Lippman, S.M., & Hong, W.K. (2002). Cancer prevention by

delay. Clinical Cancer Research, 8, 305-313.

Livingston, P.O., Ritter, G., Srivastava, P., Padavan, M., Calves, M

...

...of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Research, 49, 7045-7050.

Mitchell, M.S. (1998). Perspective on allogeneic melanoma lysates in active...

...melanoma. Journal of Clinical Oncology, 10, 1158-1164.

Morton, D.L. (2001). Cyoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma. Tumori, 87, S57-59.

Morton, D.L., & Barth, A. (1976). Vaccine therapy for malignant melanoma. CA: A Cancer Journal for Clinicians, 4 6, 225-244.

Morton, D.L., Foshag, L.J., Hoon, D...

...immunotherapy with a new polyvalent melanoma vaccine. Annals of Surgery, 216, 463-482.

National Comprehensive Cancer Network (NCCN). (2004). Clinical practical guidelines in oncology--Melanoma. Retrieved from www.nccn.org Sondak...

...Tuthill, R.J., Kempf, R.A., Unger, J.M., Sosman, J.A., et al. (2002).

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. Journal of Clinical...

...Lin, P.Y., Flaherty, L.E., Park, M.S., Kempf, R.A., et al. (2002a).

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. Journal of Clinical Oncology, 20

...

...R.E., Irie, R.F., & Morton, D.L. (1985). Immunogenicity of melanoma-associated gangliosides in cancer patients. International Journal of Cancer, 35, 607-612.

Takahashi, T., Chang, C., Morton, D.L., & Irie, R.F. (1995). IgM

...

...by active immunization correlated with survival in melanoma patients.

Proceedings of the American Association for Cancer Research, 36, 485.

Takahashi, T., Johnson, T.D., Nishinaka, Y., Morton, D.L., & Irie, R... (2003). Granulocyte macrophage colony-stimulating factor added to a multipptide vaccine for resected Stage II melanoma. Cancer, 97, 186-200.

Table 1.

Current AJCC Staging System for Cutaneous Melanoma

Stage	Characteristics
IA Tumor	
(less than or equal to) 1.0 mm without ulceration;	
no lymph node involvement; no distant metastases	

IB Tumor
(less than or equal to) 1.0 mm with ulceration or Clark
level IV or V; tumor
1.01-2.0 mm without ulceration; no lymph
node involvement; no distant metastases

IIA Tumor 1.01-2.0 mm with ulceration; tumor
2.01-4.0 mm without
ulceration; no lymph node involvement; no distant metastases

IIB Tumor 2.01-4.0 mm with ulceration

IIB Tumor
> 4.0 mm without ulceration; no lymph node involvement;
no distant metastases

IIC Tumor
> 4.0 mm with ulceration; no nodal involvement;
no distant metastases

IIIA Tumor
of any thickness without ulceration with 1 positive
lymph

IIIB Tumor
of any thickness without ulceration with 2-3 positive
lymph nodes

IIIC Tumor
of any thickness and 4 more metastatic lymph nodes
OR matted nodes OR in-transit...

...in-transit
met(s)/satellite(s), OR ulcerated melanoma and metastatic
lymph node(s)

IV Tumor of any thickness with any nodes and any distant
metastases

Met(s) = metastases
Ulceration = the...

...350
Antigenics Arm II Interleukin 2 +/- (AJCC Stage IV)
(closed Dacarbazine/Temozolomide +/-
Sept. 2004) complete tumor resection
(until expiration)

MEDAREX Arm I MDX alone N = 750
Arm II MDX-1379 alone...

...and in rare cases
swelling, and blistering has occurred. For vaccines using
discomfort at BCG adjuvant

, expect papules or pustule
the injection site. formation.

Assess and document * Some protocols exclude patients...

...adherence to protocol specimen
vaccines requiring handling guidelines (how to send resected
fresh or frozen tumor
to facility for vaccine production).
tissue/tumor

: Specimen packaging shipping and handling
per protocol and federal guidelines (large
fines for persons and...

...immunity (several mechanisms).

* Imiquimod--binds to Tol-7 receptor and stimulates T cells, expression
of tumor
anti-apoptotic markers, promote local release of cytokines
IFN- α , TNF- α , GM-CSF.

Source: Demierre & Merlino, 2004

Table 5.
Melanoma Clinical Trials Web Sites

Clinical Trials Search

National Cancer Institute PDQ
www.nci.nih.gov/clinicaltrials

National Institutes of Health
<http://clinicaltrials.gov/ct...>

...Group
www.swog.org

Eastern Cooperative Oncology Group
<http://ecog.dfci.harvard.edu/>

National Comprehensive Cancer Network
<http://www.nccn.org/>

Centerwatch
www.centerwatch.com

General Melanoma Information

National Cancer Institute (Melanoma page)
www.nci.nih.gov/cancertopics/types/melanoma

American Cancer Society
www.cancer.org

Mike's Page--The Melanoma Resource Center

(Exceptional private nonprofit informational site. Provides translation...

...Melanoma Patient's Information Page
www.mpip.org

Oncolink
www.oncolink.upenn.edu

The Skin Cancer Foundation
<http://www.skincancer.org/melanoma/index.php>

Melanoma Net--The American Academy of Dermatology...

Descriptors:
...Cancer--

Product/Industry Names:
8000432 (Cancer Therapy...

>>>W: KWIC option is not available in file(s): 399

? t s17/3/1

17/3/1 (Item 1 from file: 73) Links
Fulltext available through: STIC Full Text Retrieval Options
EMBASE

(c) 2008 Elsevier B.V. All rights reserved.
0082054227 EMBASE No: 2007474867

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Brichard V.G.; Lejeune D.
Cancer Immunotherapeutics R and D, GlaxoSmithKline Biologicals, Belgium
Author email: vincent.brichard@gskbio.com
Corresp. Author: Brichard V.G.
Corresp. Author Affil: Cancer Immunotherapeutics R and D, GlaxoSmithKline Biologicals, Belgium
Corresp. Author email: vincent.brichard@gskbio.com

Vaccine (Vaccine) (United Kingdom) September 27, 2007 , 25/SUPPL. 2 (B61-B71)
CODEN: VACCD ISSN: 0264410X
Publisher Item Identifier: S0264410X07007049
Item Identifier (DOI): 10.1016/j.vaccine.2007.06.038
Document Type: Journal ; Review Record Type: Abstract
Language: English Summary language: English
Number of References: 92

? d s

Set	Items	Description
S1	139	S CPG AND MAGE AND CANCER
S2	27025	S IL (W) 18 OR INTERLEUKIN (W) 18
S3	3	S S1 AND S2

S4 3 RD (unique items)
S5 139 S S1
S6 68 RD (unique items)
S7 1 S S6 AND 7909
S8 1 S TUMOR AND MAGE AND ADJUVANT AND CPG (W) 7909
S9 33 AU='GERARD, CATHERINE' FROM 5, 34, 35, 45, 65, 71, 73, 91, 98, 135, 144, 149, 155, 156, 159, 162, 164, 172, 266, 369, 370, 399, 434, 444, 467
S10 0 S S1 AND S9
S11 31 AU='JONAK, ZDENKA L.' FROM 5, 34, 35, 45, 65, 71, 73, 91, 98, 135, 144, 149, 155, 156, 159, 162, 164, 172, 266, 369, 370, 399, 434, 444, 467
S12 0 S S1 AND S11
S13 1177 S (CANCER OR TUMOR OR TUMOUR) AND CPG AND ADJUVANT
S14 0 S S11 AND S13
S15 8258 S MAGE
S16 23 S S13 AND S15
S17 23 RD (unique items)

2/2008 9:21:13 AM

?